Jaguar Health Inc（JAGX）财务数据JAGXJaguar Health Inc

Jaguar Health Inc (JAGX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Human Health, accounting for 96.1% of total sales, equivalent to $2.86M. Another important revenue stream is Animal Health. Understanding this composition is critical for investors evaluating how JAGX navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Jaguar Health Inc maintains a gross margin of 15.84%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -620.16%, while the net margin is -1045.06%. These profitability ratios, combined with a Return on Equity (ROE) of -865.16%, provide a clear picture of how effectively JAGX converts its operational activities into shareholder value.

In the context of the broader market, JAGX competes directly with industry leaders such as MBIO and SILO. With a market capitalization of $4.50M, it holds a significant position in the sector. When comparing efficiency, JAGX's gross margin of 15.84% stands against MBIO's N/A and SILO's -14.77%. Such benchmarking helps identify whether Jaguar Health Inc is trading at a premium or discount relative to its financial performance.

Jaguar Health's financial performance shows troubling trends, with a net income loss of $12.7 million in Q2 2026 and a staggering year-to-date change of -97.68%. The gross margin has fluctuated significantly, dropping to 15.84% in Q2 2026, indicating challenges in maintaining profitability. The company has also reported a high forward P/E ratio of 200, suggesting that the stock may be overvalued given its current financial struggles.